NEW YORK, Aug 1 –Corvas International has signed a multi-year subscription to Incyte’s LifeSeq Gold database, the companies said Wednesday.

Corvas said it would use the database for its cancer research activities. The San Diego-based company is currently researching serine proteases to determine their potential as solid tumor drug targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.